An interventional study of Total hip arthroplasty via direct anterior approach (manual, non-robotic) and Total hip arthroplasty via posterior approach (manual, non-robotic) in Osteoarthritis (OA) of the Hip, sponsored by Ochsner Health System. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Ochsner Health System · Not applicable, Interventional, and Treatment
Among 1,029 studies in Osteoarthritis with a site in United States — 117 open to participants now, 177 under way, 14 of them phase 3. Osteoarthritis · United States.
Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 593rd largest by planned enrollment of the 832 interventional ones that give a count, is one of 37 that started in 2025, is one of 437 with no phase, reaches primary completion later than 114 of the 176 other live ones, and was the 1,000th registered.
2,974 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →117 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Pfizer · Sites in United States, Canada
Margaret L Gourlay, MD, MPH · Sites in United States
Columbia University · Sites in United States
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 287 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 72 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,029 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 155 · Phase 3 143 · Phase 4 74
First in 1977; this study’s year is marked. 37 started in 2025.
This study's planned enrollment of 48 is below the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 100 across the 832 interventional studies, 114 across the 188 observational. Of the 758 that completed or were terminated, 338 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
473 of 1,029 have an industry lead sponsor. The 10 most frequent:
Ochsner Health System is the lead sponsor of 57 studies on the registry; 7 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ochsner Health System has 2 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
59 of the studies in Osteoarthritis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06269705Phase 3Pacira Pharmaceuticals, IncZILRETTA in Subjects With Shoulder Osteoarthritis | 2026-12 |
| NCT05992883Phase 3Mayo ClinicNSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis | 2026-12-31 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
Among the 1,029 studies in Osteoarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the gait biomechanics following THA on 3 groups of subjects undergoing DAA (manual) and PA (manual and robotic) surgical approaches.
Single-center, three-arm, partially randomized interventional study comparing gait biomechanics after primary total hip arthroplasty (THA) via (1) manual direct anterior approach (DAA), (2) manual posterior approach (PA), and (3) robotic-assisted posterior approach (rPA). One surgeon's patients are randomized to DAA vs PA; the second surgeon's patients receive rPA per routine practice. Outcomes assessors are blinded (motion-capture suit conceals dressings/scars). Gait and sit-to-stand analyses are performed pre-op and at 6 and 12 weeks post-op using a Vicon motion capture system with force plates and surface EMG. Patient-reported outcomes are collected with standard instruments. The trial evaluates short-term biomechanical recovery and patient-reported outcomes across approaches.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The DAA utilizes an internervous and intermuscular approach, preserving abductor and posterior soft tissues, and is associated with reduced dislocation rates and accelerated early recovery.⁶ However, it carries a steep learning curve and an elevated risk of lateral femoral cutaneous nerve neuropraxia.
Procedure: Total hip arthroplasty via direct anterior approach (manual, non-robotic)
PA remains the most commonly used technique worldwide, offering extensile exposure and preserved abductor function, though its historical association with increased dislocation risk has necessitated meticulous capsular and soft-tissue repair.
Procedure: Total hip arthroplasty via posterior approach (manual, non-robotic)
Robotic-assisted THA introduces computer-navigated precision into implant alignment and biomechanical restoration. Contemporary systems (e.g., MAKO) offer intraoperative haptic guidance and preoperative CT-based planning to improve component placement accuracy.
Procedure: Robotic-assisted total hip arthroplasty via posterior approach
Primary THA performed via a direct anterior approach without robotic assistance
Primary THA performed via a posterior approach without robotic assistance
Primary THA via posterior approach using pre-op CT-based planning and intra-op robotic assistance
Walking speed during level gait (m/s)
Mean self-selected walking speed measured over instrumented walkway during motion-capture trials.
Time frame: Change from baseline (pre-op) to 6 weeks and 12 weeks post-op.
Peak hip abduction moment during stance (Nm/kg)
Maximum external hip abduction moment during stance, normalized to body mass.
Time frame: Change from baseline (pre-op) to 6 weeks and 12 weeks post-op.
EMG- Gluteus medius peak activation at initial contact/loading response
Peak normalized surface EMG amplitude of the operated-side gluteus medius measured during the initial contact/loading response of level walking. EMG is sampled synchronously with motion capture and force plates, band-pass filtered (\~20-450 Hz), rectified, and low-pass filtered (\~6 Hz) to form a linear envelope. Strides are time-normalized to 0-100% gait cycle; the peak is extracted within 0-10% of the gait cycle (heel strike through loading response). Amplitude is normalized to the participant's maximum voluntary isometric contraction (%MVIC). Participant-level values are the mean of valid trials at each visit.
Time frame: Change from baseline (pre-op) to 6 weeks and 12 weeks post-op.
postoperative complications-(participants with ≥1 event, %)
Postoperative complications include, but are not limited to: Surgical \& Local Complications Dislocation Prosthetic Joint Infection (Early or Late) Aseptic Loosening Periprosthetic Fracture Implant Wear (Osteolysis) Wound Complications (Hematoma, Dehiscence) Nerve or Vascular Injury Leg Length Discrepancy Heterotopic Ossification Implant Failure or Breakage Adverse Local Tissue Reaction (Metallosis) Tendon/Muscle Dysfunction Medical \& Systemic Complications Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Cardiovascular Events (Heart Attack, Stroke)
Time frame: through study completion, an average of 1 year
Patient Reported Outcome Measures-HOOS
Hip Disability and Osteoarthritis Outcome Score. Questionnaire. Range 0-100, higher=better
Time frame: Baseline; 6 weeks; 12 weeks; 12 months; change from baseline - Score (0-100)
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Nov 2027, 25 months after the start.
Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 52. This study's planned 25 months is close to that.
Counting every sponsor, half of 713 studies reached it within 29 months; a quarter within 11 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ochsner Health System